The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

(Alliance News) - GSK PLC on Monday said linerixibat has been accepted for review by the European Medicines Agency for the treatment of intense itching caused by a rare autoimmune liver disease.

GSK PLC a annoncé lundi que le linerixibat a été accepté pour examen par l'Agence européenne des médicaments dans le ...

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

GSK plc (LSE/NYSE:GSK) a annoncé lundi que l'Agence européenne des médicaments (EMA) a accepté d'examiner sa demande d'autorisation de mise sur le marché pour le linerixibat, un traitement expérimenta ...

– GSK a annoncé lundi que l’Agence européenne des médicaments a accepté d’examiner la demande d’autorisation de mise sur le ...

GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with ...

Le linerixibat agit en inhibant le transporteur iléal des acides biliaires (IBAT), réduisant les médiateurs du prurit en circulation. La FDA et l’EMA ont toutes deux accordé au médicament la ...

If approved, linerixibat could address an area of high unmet medical need for patients living with cholestatic pruritus and related sleep interference. Year to date, shares of GSK have rallied 23. ...

Linerixibat was also associated with significant improvements in key secondary endpoints vs placebo, including itch score at week 2 (P <.001) and itch-related sleep interference over 24 weeks (P ...